Our Experts

Name: Si-Yu Wang
Title: Professor
Email: wangsy@sysucc.org.cn

Dr. Si-Yu Wang is currently a Professor in the Department of Thoracic Oncology, at Sun Yat-sen University Cancer Center. He specializes in the multidisciplinary treatment of thoracic neoplasms, including lung cancer, breast cancer, and esophageal cancer. He is the president of Guangdong Association Study of Thoracic Oncology (GASTO). He is now leading several clinical trials in China. He has published more than 40 peer-reviewed papers, including some renowned journals such as Annals of Oncology, Journal of Thoracic Oncology, Cancer, Lung Cancer and Annals of Surgical Oncology.


Design and conduct of phase II and III trials on thoracic neoplasms. 

1982-1988, Sun Yat-sen University. 

Selected publications

1. Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA-N2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy. Li N, Zeng ZF, Wang SY*, Ou W, Ye X, Li J, He XH, Zhang BB, Yang H, Sun HB, Fang Q, Wang BX. Ann Oncol 2015. 

2. Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non-small cell lung cancer. Ou W, Sun HB, Ye X, Zhang BB, Yang H, Fang Q, Li P, Wang SY*. J Thorac Oncol 2010. 

3. The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected locally advanced non-small cell lung cancer. Sun HB, Wang SY*, Ou W, Zhang BB, Yang H, Fang Q. Lung Cancer 2010. 

4. Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001). Ou W, Li N, Wang SY*, Li J, Liu QW, Huang QA, Wang BX. Cancer 2016. 

5. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma. Li N, Ou W, Yang H, Liu QW, Zhang SL, Wang BX, Wang SY*. Cancer 2014. 

6. Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study. Li N, Ou W, Ye X, Sun HB, Zhang L, Fang Q, Zhang SL, Wang BX, Wang SY*. Ann Surg Oncol 2014. 

7. Circulating Tumor DNA Analyses as a Potential Marker of Recurrence and Effectiveness of Adjuvant Chemotherapy for Resected Non-Small-Cell Lung Cancer. Kuang PP, Li N, Liu Z, Sun TY, Wang SQ, Hu J, Ou W, Wang SY*. Front Oncol 2021. 

8. Prognostic role of the ABO blood types in Chinese patients with curatively resected non-small cell lung cancer: a retrospective analysis of 1601 cases at a single cancer center. Li N, Xu M, Li CF, Ou W, Wang BX, Zhang SL, Xu PF, Yuan C, Huang QA, Wang SY*. Chin J Cancer 2015

9. Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced non-small-cell lung cancer. Sun HB, Ou W, Li Y, Fang Q, Qin J, Zhang L, Wang SY*. Clin Lung Cancer 2013. 

10. Risk of cerebral metastases for postoperative locally advanced non-small-cell lung cancer. Wang SY*, Ye X, Ou W, Lin YB, Zhang BB, Yang H. Lung Cancer 2009. 

Updated March 2021 by International Office, Sun Yat-sen University Cancer Center

Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.